Sugi Predict

Sugi Predict / Compounds / Glutarate

Glutarate

Glutarate

SCHEMBL5406232

NC(=O)N1CCCCCC1.O=C(O)CCCC(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ ATM Q13315 1/20 0.50
▸ SLC22A6 Q4U2R8 1/20 0.46
▸ L3MBTL1 Q9Y468 4/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ HTT P42858 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ BLM P54132 2/20 0.39
▸ GABRR3 A8MPY1 1/20 0.39
▸ GABRP O00591 1/20 0.39
▸ GABRD O14764 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL5411814 0.91 SMN1; SMN2 (0.47) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL4055560 0.90 CYP1A2 (0.48) CYP1A2MAPK1SMN1; SMN2ATMSLC22A6
Succinic Acid SCHEMBL5403541 0.89 ATM (0.44) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
Beta-Alanine SCHEMBL27722682 0.86 CYP1A2 (0.42) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
Hydrochloric Acid SCHEMBL8356810 0.83 LMNA (0.59) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
Beta-Alanine SCHEMBL9092097 0.83 ATM (0.40) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
Glycine SCHEMBL8830859 0.83 GLRA1 (0.46) CYP1A2MAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL23963672 0.82 ALDH1A1 (0.55) ATML3MBTL1KMT2AMEN1HTT
SCHEMBL14511334 0.82 ALDH1A1 (0.55) ATML3MBTL1KMT2AMEN1HTT
SCHEMBL1363949 0.82 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173024-B2 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use ORION CORPORATION (FI) 2007-02-06 — — US disclosed
US-20050020677-A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use ORION CORPORATION (FI) 2005-01-27 — — US disclosed
EP-1401810-A1 COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE ORION CORPORATION (FI) 2004-03-31 — — EP disclosed
WO-2003004468-A1 COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE ORION CORPORATION (FI) 2003-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020677-A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use DNPEP, PREP, ANPEP CYP1A2 1398/4885MAPK1 2741/4885SMN1; SMN2 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.